<DOC>
	<DOC>NCT00735787</DOC>
	<brief_summary>Evaluate the efficacy and safety of a 16-week course of Humira (adalimumab) compared to placebo in adults with chronic plaque psoriasis of the hands and/or feet and the sustainability of response for 12 additional weeks.</brief_summary>
	<brief_title>Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Adult with Diagnosis of chronic plaque psoriasis of the Hands and Feet for at least 6 months, with a PGA &gt;/=3 and candidates for systemic therapy; Patients in good general health Able to selfadminister injections Negative chest xray (CXR) and purified protein derivative (PPD) test, unless willing to start antituberculosis (TB) prophylaxis Previous treatment with HUMIRA® Required mediation stability or washouts for: systemic corticosteroids (28 days), other investigational agent, other systemic therapies for psoriasis, ultraviolet B (UVB), psoralen with UVA (PUVA) Other active skin diseases or skin infections Diagnosis of palmoplantar pustulosis; erythrodermic psoriasis, pustular psoriasis, medicationinduced or exacerbated psoriasis or new onset of guttate psoriasis Evidence of dysplasia or history of malignancy (Other than a successfully treated nonmetastatic cutaneous squamous cell, basal cell carcinoma or localized carcinoma in situ of the cervix); History of listeriosis, histoplasmosis, chronic or active Hepatitis B infection, human immunodeficiency virus (HIV) infection, immunodeficiency syndrome, chronic recurring infections or active tuberculosis (TB); History of moderate to severe congestive heart failure, Recent cerebrovascular accident and any other condition which, in the opinion of the investigator, would put the subject at risk; History of central nervous system (CNS) demyelinating disease or neurologic symptoms suggestive of CNS demyelinating disease; History of clinically significant drug or alcohol abuse in the last 12 months; Infection(s) requiring treatment with intravenous (IV) antibiotics, IV antivirals, or IV antifungals within 30 days prior to Baseline or oral antibiotics, oral antivirals, or oral antifungals within 14 days prior to Baseline; Known hypersensitivity to the excipients of HUMIRA® as stated in the label; Female subjects who are pregnant or breastfeeding or considering becoming pregnant during the study. Prior exposure to Tysabri® (natalizumab)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>